Deals Of The Week: VBI Vaccines/Epixis, Vanderbilt/Seaside, Cellectis/Cellartis
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Vanderbilt Research Into GlyT1 Inhibition May Result In New Approach To Treating Schizophrenia
Vanderbilt's Center for Neuroscience Drug Discovery licenses three preclinical GlyT1 candidates to Karuna Pharmaceuticals, one of three business development actions by the center in recent weeks.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.